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Abstract
Background: SH3 containing Lymphocyte Protein (SLY1) is a putative adapter protein exclusively
expressed in lymphocytes which is involved in antigen receptor induced activation. We previously
have generated SLY1Δ/Δ mice harbouring a partial deletion in the N-terminal region of SLY1 which
revealed profound immunological defects in T and B cell functions.
Results: In this study, T cell development in SLY1-/- and SLY1Δ/Δ mice was analysed ex vivo and upon
cultivation with the bone marrow stromal cell line OP9. SLY1-deficient thymocytes were
compromised in inducing nutrient receptor expression and ribosomal protein S6 phosphorylation,
indicating a defect in mTOR complex activation. Furthermore, SLY1 was identified as a novel anti-
apoptotic protein required for developmental progression of T cell precursors to the CD4+CD8+
double-positive stage by protecting from premature programmed cell death initiation in developing
CD4-CD8-  double-negative thymocytes. In addition, SLY1 phosphorylation was differentially
regulated upon Notch ligand-mediated stimulation and expression of the preTCR.
Conclusion: Thus, our results suggest a non-redundant role for SLY1 in integrating signals from
both receptors in early T cell progenitors in the thymus.
Background
T cell development mainly takes place in the thymus and
is characterized by defined developmental stages ulti-
mately leading to the generation of mature αβ and γδ T
cells. The earliest T cell progenitors entering the thymus
via the bloodstream lack CD4 and CD8 expression and
are therefore called double-negative (DN). DN thymo-
cytes can be further subdivided into four successive devel-
opmental stages according to the expression of CD25 (IL-
2 receptor α chain) and CD44 (Pgp-1) [1,2]. The most
immature progenitors (DN1) are assigned to the
CD44+CD25- subset. Upregulation of CD25 marks pro-
gression to the DN2 stage (CD44+CD25+). Irreversible
commitment to the T cell lineage is not established until
the DN3 stage, which can be identified as the CD44-
CD25+ DN subset. In this cell population, rearrangement
of the TCRβ- or TCRγδ genes is accomplished, leading to
either development into the αβ- or the γδ lineage. For αβ
T cells, a successfully generated TCRβ chain leads to for-
mation of the preTCR via pairing with the preTα chain
and CD3 signalling complexes. Thymocytes failing to gen-
erate a preTCR undergo programmed cell death [3]. Thy-
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mocytes otherwise destined to induce programmed cell
death are rescued from apoptosis upon preTCR genera-
tion. This event is termed β-selection, leading to extensive
cellular expansion and cessation of further TCRβ locus
recombination (allelic exclusion). Cells which have
passed this developmental checkpoint downregulate
CD25 to become DN4 cells and then proceed to the
numerically dominant CD4and CD8 double-positive
(DP) stage. Lymphocytes evading cell death are frequently
the origin of malignant transformations [4,5]. Although
of high clinical relevance, the regulation of pro- and anti-
apoptotic processes at this specific stage of development is
still incompletely understood.
In the past years, it has been established that for commit-
ment to the T cell lineage Notch signalling is essential [6-
9]. In combination with the preTCR, Notch induces pro-
liferation and differentiation to DP thymocytes [10,11].
More recently, Notch ligand engagement was additionally
shown to be crucial for controlling progenitor cell metab-
olism by activating Phosphatidyl-Inositol-Kinase-1 (PDK-
1), Akt and the mammalian Target of Rapamycin (mTOR)
complex [12,13]. Notch- and preTCR-dependent upregu-
lation of mTOR induces expression of the nutrient recep-
tors CD71 (transferrin receptor) and CD98 (amino acid
transporter). This is, together with the PDK-1- and mTOR-
dependent activation of AGC-serine kinases like S6 Kinase
1 and Ribosomal S6 Kinase, a key event for cell mass
increase and induction of a proliferation-competent sta-
tus, eventually leading to six to ten consecutive rounds of
cell division after passage of the β-selection checkpoint.
SH3 Lymphocyte Protein (SLY1) is a putative adapter pro-
tein containing a SH3- and SAM-domain. It constitutes
the first described member of a family of highly homolo-
gous proteins conserved in mammals whose molecular
function is still elusive. The protein SLY1 consists of 380
amino acids and is exclusively expressed in lymphocytes
[14]. It has been originally found in an adhesion assay
screen using a T cell lymphoma cDNA library. SLY1 has
been independently identified by another group during a
screen for new serine kinase substrates [15]. There it was
shown that SLY1 is specifically phosphorylated upon T
cell receptor (TCR)-triggering or stimulation with phorbol
esters at Serin27. This phosphorylation could be pre-
vented by Protein Kinase C (PKC)- or PI3Kinase-inhibi-
tors, however, the directly phosphorylating kinase has not
been identified to date. Further hints for a possible
involvement of SLY1 in the TCR-transduction pathway
were delivered by the immune-compromised phenotype
of mice expressing a truncated SLY1 protein. This trunca-
tion resulted in aberrant subcellular localisation of the
remaining protein SLY1Δ which is lacking part of the
bipartite nuclar localisation sequence and the known
phosphorylation site [16]. Furthermore, it was shown that
SLY1 plays a substantial role in the development and acti-
vation of immune cells, although the underlying mecha-
nism of this phenotype could not be clarified [16,17].
Two additional highly homologous proteins have been
described: SLY2, also termed SAMSN1/NASH1/HACS1, is
more broadly expressed in haematopoietic tissues,
endothelial cells and myeloid leukemias and myelomas
[18,19]. SLY2 has been implicated in inducing a plasma-
cell-like phenotype when overexpressed in B cells and has
been linked to the inhibitory receptor PirB [20]. The SLy2
locus lies in a region which is frequently disrupted in
translocation events leading to haematopoietic malignan-
cies [18]. Most recent data suggest the involvement of
SLY2 as tumour suppressor in human lung cancer [21].
SLY3 (SASH1) is expressed in almost all tissues and has
been repeatedly described as a tumour suppressor based
on its frequent downregulation in breast cancer and colon
carcinoma [22,23].
In this study, mice harbouring a complete deletion of
SLY1 protein were generated and thymocyte development
was subsequently analysed. Thereby, an important role
for the orphan adapter protein SLY1 at the thymocyte DN
to DP progression was identified, leading to a reduction in
thymic cellularity by about 50%. SLY1-deficient thymo-
cytes were compromised in inducing nutrient receptor
expression and ribosomal protein S6 phosphorylation,
indicating a defect in mTOR complex activation and sug-
gesting a role for SLY1 in integrating signals derived from
the preTCR and from the Notch receptor. This defect
resulted in abnormally increased deletion of precursor
cells by induction of programmed cell death, yielding a
strong reduction in DP thymocyte numbers. Interestingly,
SLY1Δ mice expressing a protein harbouring a deletion of
81 amino acids in the N-terminal region of SLY1 exhibited
an identical phenotype. Thus, a non redundant role for
this region comprising the phosphorylation site and part
of the nuclear localisation sequence (NLS) could be
assigned.
Results
To elucidate the role of SLY1, mice expressing a truncated
SLY1 protein (SLY1Δ) have been generated previously
[16]. SLY1Δ/Δ mice display a severe defect in lymphocyte
numbers as determined by measuring cellularity of lym-
phoid organs and lymphocyte activation in a mixed lym-
phocyte reaction. As the expression of a truncated protein
can display unpredictable results, the phenotype of SLY1Δ/
Δ mice may actually not reflect the precise molecular role
of SLY1 in lymphocyte development and activation.
Therefore, SLY1-/--mice were generated by injection of E14
embryonic stem cells carrying a targeted homologous
inactivation of SLY1. Figure 1A shows the arrangement of
the first exons of the genomic SLy1 locus and of the target-
ing vector. After homologous recombination of the target
vector with the SLy1 locus, a neomycin cassette is integratedBMC Immunology 2009, 10:38 http://www.biomedcentral.com/1471-2172/10/38
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in reverse orientation in exon 1. Arrows indicate the posi-
tion of screening oligonucleotides which lead to a 1.2 kb
versus 0.7 kb PCR product for the wildtype (wt) and
knockout (ko) allele, respectively (Figure 1B). Germ line
transmission of the ko allele was confirmed by Southern
blotting (Figure 1C). Complete inactivation of the SLy1
gene was verified by Western blot (Figure 1D) using two
different antibodies recognizing different epitopes of
SLY1 protein.
Reduced cellularity of lymphoid organs
SLY1-/-  mice were born at normal Mendelian ratios,
appeared healthy and were fertile. SLY1Δ/Δ mice have been
reported to display diminished lymphoid organ cellular-
ity [16]. To this regard, the impact of a complete SLY1-
deficiency was assessed. Analysis of lymphoid organ cell
count revealed a significant reduction of lymphoid organ
cell numbers of SLY1-/- mice compared to SLY1+/+ litterma-
tes (Figure 2A). Cell numbers of thymi were reduced by
46%, splenocyte cellularity by 42% and lymph node cel-
lularity by 51%. The mean number of macroscopically
visible Peyer's patches also was clearly reduced to 7.8 +1.8
compared to 10.1 +1.4 in wt littermates (Figure 2B). Nev-
ertheless, major SLY1-/- splenic lymphocyte subpopula-
tion ratios as determined by FACS were grossly normal
except a reduction in percentages of marginal zone B cells
(Figure 2C). Overall, all SLY1-/- lymphocyte subpopula-
tions were decreased in cell number due to the smaller
Generation of SLY1 ko mice Figure 1
Generation of SLY1 ko mice. A. Scheme of the sly1 genomic locus, targeting vector and inserted neomycin cassette after 
homologous recombination. The neomycin cassette is inserted in inverted orientation directly after the starting ATG. B. 
Screening PCR with genomic tail DNA and primers as described in material and methods. C. Southern blot after digestion of 
genomic tail DNA with EcoRV and detection with 32P-labeled probe depicted in A. D. Western Blot assessing the successful 
inactivation of the sly1 gene using two different SLY1-specific antibodies and β-actin as loading control.
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organ size (Figure 2D), even though major B and T cell
subpopulation ratios were normal. In summary, these
data are strikingly reminiscent of the previously described
phenotype of SLY1Δ/Δ mice, which also displayed a reduc-
tion in cellularity of lymphoid organs, namely spleen, thy-
mus, lymph nodes and Peyer's patches [16].
Delayed T cell development
As both partial and complete deletion of SLY1 protein had
an obviously deleterious effect on thymocyte cell number
leading to a reduction of about 50% of wt levels, SLY1-
dependent thymocyte development was examined more
closely. SLY1 is expressed in all major thymocyte subsets,
as determined by RT-PCR (see Additional file 1). To gain
a better understanding of the impact of the N-terminal
truncation in the SLY1 protein versus complete deletion,
SLY1Δ/Δ thymocytes were included in the following exper-
iments. CD4- and CD8-staining of total thymocytes
revealed no apparent differences in percentages of DP and
single-positive (SP) cells in the thymus (Figure 3A, left
panel). Comparable expression of TCRβ, CD69 and CD5
on DP thymocytes indicated normal TCR signalling and
positive selection events in SLY1-targeted thymocytes
(Figure 3A, right panel). In line with the reduced thymo-
cyte cellularity, SLY1-/- and SLY1Δ/Δ mice had markedly
reduced total numbers of CD4+ and CD8+ DP and SP thy-
mocytes, only a minor decrease in DN thymocyte counts
was observed (Figure 3B, left panel). These results sug-
gested a partially delayed development of DN to DP thy-
mocytes in the absence of a functional SLY1 protein. In
accordance with this hypothesis, a doubling in the per-
centage of DN cells in SLY1-/- and SLY1Δ/Δ thymi was
Reduced cellularity of lymphoid organs in SLY1-/--mice Figure 2
Reduced cellularity of lymphoid organs in SLY1-/--mice. A. Mean cell count of thymus, spleen and pooled axial and 
inguinal lymph nodes was determined (n = 4). B. Reduced number of visible Peyer's patches in SLY1-/--mice. C. FACS analysis 
of splenic lymphocyte subpopulations. T cells were determined as Thy1.2+, B cells as B220+, marginal zone B cells as 
CD21highCD23- of B220+, and NK cells as CD3-CD56+ (n = 9). D. Absolute cell counts/spleen (n = 9). **p ≤ 0.01; *** p ≤ 0.001.
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observed (Figure 3B middle and right panel). This
prompted us to further analyse the DN subset frequencies
based on the expression of CD25 and CD44 (Figure 3C).
We observed a slight decrease in DN1, a slight increase in
DN2 and DN3 ratios in SLY1-/- and SLY1Δ/Δ thymi, and a
slight decrease in DN4. Therefore, SLY1 appears to be
required for developmental progression in all four thymic
DN subsets and the block in development could not be
assigned to a specific DN stage, providing a first hint that
SLY1 expression is especially critical in thymic DN pro-
genitor cells.
Defect in proliferation and differentiation in vitro
The partial block in developmental progression of DN
thymocytes lacking functional SLY1 protein indicated that
proliferation of DN thymocytes in SLY1-defective mice
might be impaired. To test this hypothesis, we analysed
SLY1-dependent thymocyte proliferation and differentia-
tion in vitro. To this end, the bone marrow stromal cell
line OP9 was used allowing in vitro differentiation of DN
to DP thymocytes induced by presentation of the Notch
ligand Delta-like 1 (DL-1) on the surface of OP9 cells
[6,24]. Congruent with published data, sorted DN thymo-
cytes proliferated and upregulated CD4- and CD8-expres-
sion dependent on the presence of Notch ligand DL-1
after three and six days of cultivation on OP9 cells (Figure
4A, B and data not shown). As expected from previously
observed  ex vivo data, we found a markedly reduced
expansion rate of sorted SLY1-/- and SLY1Δ/Δ DN thymo-
cytes upon cultivation on OP9 cells compared to wt litter-
Block in thymocyte CD4-CD8- (DN) to CD4+CD8+ (DP) differentiation Figure 3
Block in thymocyte CD4-CD8- (DN) to CD4+CD8+ (DP) differentiation. A. Total thymocyte CD4- and CD8-expres-
sion was determined by FACS analysis (left panel). Histograms (right panel): Surface expression of TCRβ, CD69 and CD5 on 
gated CD4+CD8+ thymocytes. B. Cell count of DN, DP or CD4- and CD8-single positive (SP) thymocytes (left panel). Gating 
(middle panel) and percentage of DN thymocytes relative to total thymocytes (right panel). C. DN thymocytes were gated as 
shown in B and a subset analysis according to expression of CD44 and CD25 was performed. DN1 = CD44+CD25-; DN2 = 
CD44+CD25+; DN3 = CD44-CD25+; DN4 = CD44-CD25-. Dot plots show representative data of three independent experi-
ments (n = 3). *p ≤ 0.05; **p ≤ 0.001; *** p ≤ 0.0005.
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mates (Figure 4B and 4C, left panel). Additionally, the
differentiation of SLY1-/- and SLY1Δ/Δ DN thymocytes was
diminished relative to littermate controls (Figure 4C, right
panel). If sorted DN3 cells were used, differentiation was
equally affected, also adding IL-7 to the medium gave sim-
ilar results (see Additional file 2).
Partially impaired activation of mTOR-complex in SLY1-
defective DN thymocytes
One of the cellular outcomes of DN thymocytes success-
fully passing the β-selection check point is the upregula-
tion of metabolic activity. This is a prerequisite to cope
with the increasing energy demands at this developmental
stage needed to allow for the upcoming extensive prolifer-
ation and differentiation of DN to DP thymocytes. Of par-
ticular importance in this context is the activation of the
Rapamycin-sensitive mTOR-complex eventually resulting
in an increase in cell mass and subsequent induction of
cell division. A first hint for a blunted mTOR-dependent
activation in SLY1-/- and SLY1Δ/Δ thymocytes came from
the observation of a reduced frequency of thymocytes
with increased cell size ex vivo and after OP9 DL-1 culture
(see Additional file 3 and Figure 5B left panel)[25]. Sev-
eral key targets of mTOR in activated DN thymocytes have
been identified so far, their activation or induced expres-
sion being strictly dependent on the combined engage-
ment of a successfully rearranged preTCR and Notch
receptor [11-13]. Well reported events at this develop-
mental stage are the activation of S6 Kinase and upregula-
tion of the nutrient receptors CD71 and CD98, all of
which have been shown to be Rapamycin-sensitive [13].
First, mTOR activation in SLY1+/+ thymocyte T cell precur-
sor populations ex vivo and after cultivation for 12 h on
OP9 DL-1 cells was analysed. This was accomplished by
determination of cell size, phosphorylation of ribosomal
protein S6, CD71 and CD98 expression as surrogate
markers for mTOR activity (Figure 5A). In line with pub-
lished data, activation of mTOR in DN thymocytes is
absolutely dependent on preTCR-expression ex vivo and in
vitro. Furthermore, mTOR activation strictly requires
Notch signalling (see Additional file 3) and can be inhib-
ited by addition of Rapamycin in vitro. Next, this single-
cell based analysis was extended to SLY1-/- and SLY1Δ/Δ
thymocytes ex vivo and after 12 h culture on OP9 DL-1
cells (Figure 5B). In summary, the activation status of
mTOR in preTCR-positive DN thymocytes of SLY1-/- and
SLY1Δ/Δ mice was clearly reduced compared to wt litterma-
tes under both conditions tested. The activation of mTOR
SLY1-targeted DN thymocytes exhibit impaired proliferation and differentiation when cultured on OP9 DL-1 cells Figure 4
SLY1-targeted DN thymocytes exhibit impaired proliferation and differentiation when cultured on OP9 DL-1 
cells. A. CD4 and CD8 FACS profiles of sorted DN thymocytes before cultivation (input, upper row), and after cultivation for 
six days on OP9 DL-1 (middle row) or on OP9 GFP control cells (lower row). B. DL-1-dependent expansion of DN thymo-
cytes after three days culture. C. Fold expansion on day three and day six (left panel). Differentiation rate (right panel) corre-
sponds to the percentage of DP cells divided by the percentage of remaining DN cells. The expansion rate was determined by 
counting triplicates and comparing to initial seeding numbers on day 0. Representative data of at least three independently per-
formed experiments is shown. *p ≤ 0.05; **p ≤ 0.005; *** p ≤ 0.001.
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in the absence of Notch signalling or in preTCR-negative
thymocytes was equally low (see Additional file 3 and
data not shown). These results suggest a defect in inducing
mTOR-mediated activation signals in a subset of T cell
precursor cells in SLY1-/- and SLY1Δ/Δ mice in response to
developmental needs. Moreover, we propose a defect in
transmitting signals from either the preTCR or the Notch
receptor to the mTOR protein complex.
Increased apoptosis induction in SLY1-defective DN3 
thymocytes
A decrease in the expansion rate of proliferating cells can
be either mediated by alterations in cell cycle progression
or elevated apoptosis induction, or even both. To identify
the underlying mechanism for the observed proliferation
defect, sorted DN thymocytes were plated on OP9 DL-1
cells and cell cycle distribution as well as apoptosis induc-
tion was assessed. We found an equal cell cycle distribu-
tion based on DNA-staining of permeabilized cells with
DAPI (Figure 6A). Yet an increase in early (Annex-
inV+DAPI-) and late (AnnexinV+DAPI+) apoptosis induc-
tion in SLY1-targeted thymocytes was detected (Figure
6B). Therefore we hypothesized that the impaired prolif-
eration can be attributed to an increased apoptosis rate in
the absence of functional SLY1 protein. PreTCR-expres-
sion and Notch signalling have both been reported to play
pivotal roles in protecting DN thymocytes from apoptosis
at the β-selection checkpoint [10,12,26]. Interestingly,
SLY1 protein has been reported to be specifically phos-
phorylated after TCR crosslinking in peripheral T cells
[15]. It was hence reasonable to speculate a role for SLY1
downstream of the preTCR or Notch in this context. To
mTOR-signalling is diminished in developing SLY1-/- and SLY1Δ/Δ DN thymocytes Figure 5
mTOR-signalling is diminished in developing SLY1-/- and SLY1Δ/Δ DN thymocytes. Cell size, activation of S6 kinase 
and expression levels of the nutrient receptors CD71 and CD98 were determined as surrogate markers for mTOR activity in 
thymocytes. Phosphorylation of ribosomal protein S6 was used as a marker of S6 Kinase activity [25]. A. SLY1+/+ DN thymo-
cytes were analysed ex vivo and after 12 h culture on OP9 DL-1 cells. Thymocytes were further subdivided by gating on 
preTCR-negative and -positive cells. B. Activation of mTOR in preTCR-expressing SLY1+/+, SLY1-/- and SLY1Δ/Δ thymocytes 
was analysed ex vivo and after OP9 DL-1 culture in vitro for 12 hours. 20 nM Rapamycin was added as a control during the cul-
tivation period to inhibit mTOR activation. Histograms show representative data of four independent experiments (n = 4).
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Increased apoptosis of OP9 cultured DN thymocytes in the absence of functional SLY1 protein Figure 6
Increased apoptosis of OP9 cultured DN thymocytes in the absence of functional SLY1 protein. A. Cell cycle 
analysis of permeabilized DN cells after 2 days of OP9 DL-1 culture using DAPI. B. AnnexinV and DAPI staining of DN thymo-
cytes cultivated for 4 days on OP9 DL-1 cells. C. SLY1-targeting results in increased Caspase-3 activation independent of 
TCRβ-expression and Notch signalling. Sorted DN3 thymocytes were cultured on OP9 cells for 2 days and then Caspase-3 
active fragment in DN cells was analysed dependent on TCRβ-expression. D. Intracellular Caspase-3 activation in DN4 cells is 
negligible. *p ≤ 0.05; **p ≤ 0.01; *** p ≤ 0.001.
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dissect the pathways SLY1 is involved in, we cultivated
sorted DN3 cells on OP9 DL-1 and OP9 control cells to
discriminate the role of Notch signalling, and used Cas-
pase-3 active fragment as an intracellular marker for apop-
tosis induction (Figure 6C). Intracellular staining for
TCRβ-expression served to identify cells which had suc-
cessfully rearranged their TCR-β-chain and which should
therefore receive preTCR-derived proliferative and sur-
vival signals. Intracellular TCRβ-expression was similar
between wt cells and SLY1-targeted cells (data not
shown). As anticipated, Caspase-3 activation was lowest
in wt preTCR-positive DN3 thymocytes cultivated on OP9
DL-1 cells, thus receiving a preTCR-derived and a Notch-
derived pro-survival signal, accounting for approximately
2% of Caspase-3 active fragment positive thymocytes (Fig-
ure 6C, histogram overlay and diagram upper right
panel). In this setting, which physiologically corresponds
to thymocytes successfully passing β-selection, apoptosis
induction was increased 4-fold in SLY1-/- and SLY1Δ/Δ DN3
thymocytes compared to wt littermate controls. In con-
trast, thymocytes failing to rearrange the TCRβ-chain stay
TCRβ-negative and hence are increasingly prone to pro-
grammed cell death initiation. This was indeed the case:
apoptosis induction in TCRβ-negative wt DN3 thymo-
cytes was 20 times higher than in their TCRβ-positive
counterparts (compare wt apoptosis upper left with upper
right panel). Again, the percentage of Caspase-3 positive
progenitor cells was markedly increased (by 20%) in
SLY1-/- or SLYΔ/Δ cultures. Interestingly, SLY1-/- and SLYΔ/Δ
thymocytes also displayed increased susceptibility
towards programmed cell death initiation in the absence
of Notch signalling (lower part of Figure 6C). Yet wt
TCRβ-negative DN3 thymocytes cultivated on OP9 con-
trol cells were highly susceptible to apoptosis, accounting
for around 30% Caspase-3-positive cells. Though the rate
of apoptotic SLY1-/- and SLY1Δ/Δ DN3 thymocytes was ele-
vated roughly by 15% relative to wt controls (left part,
lower panel). We also observed a more than twofold
increase in Caspase-3 activation in the preTCR-positive
population of DN3 thymocytes when plated on OP9 con-
trol cells in the absence of SLY1. Thus, an overall increase
in programmed cell death was observed in both SLY1-/-
and SLY1Δ/Δ DN3 thymocytes. In general, TCRβ-expres-
sion was the major pro-survival determinant, Notch sig-
nals even were detrimental if thymocytes failed to
successfully rearrange their TCRβ-genes (compare left part
upper and lower panel). Nevertheless, Caspase-3 activa-
tion was elevated in SLY1-/- and SLY1Δ/Δ DN3 thymocytes
independent of the availability of signals from the preTCR
or the Notch receptor or even both. In summary, these
results suggest a general anti-apoptotic role of SLY1 in
DN3 thymocytes. Remarkably, programmed cell death in
DN4 cells was equally undetectable independent of SLY1-
expression (Figure 6E). This data supports a specific role
for SLY1 in protecting DN3 thymocytes during the β-selec-
tion checkpoint. To further elucidate a possible role for
SLY1 in amplifying Notch-derived signals, a titration of γ-
secretase-inhibitor (GSI) which is reported to inhibit spe-
cifically Notch receptor activation on sorted DN3 SLY+/+,
SLY1-/- and SLY1Δ/Δ thymocytes was performed (see Addi-
tional file 4). After six days of cultivation on OP9 cells, dif-
ferentiation and proliferation was assessed. Appearance of
DP cells gradually decreased with increasing GSI concen-
trations likewise did the expansion rate. At 1 μM GSI, inhi-
bition was almost complete, as assessed by comparing the
proliferation and differentiation rate with the OP9 GFP
cultivated controls. SLY1Δ/Δ and SLY1-/- thymocytes were
found to be more sensitive than SLY1+/+ thymocytes to
intermediate concentrations of GSI, supporting a function
for SLY1 in signal propagation from the Notch receptor.
However, this increased sensitivity was only very weakly
pronounced and could also be attributed to a defect in
integration of preTCR and Notch signals, as both signals
are required for proliferation.
Regulation of phosphorylation of SLY1 in thymocytes
It has been reported that SLY1 is phosphorylated at
serine27 specifically upon TCR-stimulation in human
peripheral T-lymphocytes and not upon chemokine- or
cytokine-driven stimulation [15]. This data implicated a
function of SLY1 downstream of the TCR. In murine
splenocytes, TCR-stimulation-induced phosphorylation
can also be observed, albeit there is considerable basal
phosphorylation in contrast to the situation in human
lymphocytes (Figure 7A). Likewise, SLY1 phosphorylation
in murine thymocytes is sensitive to inhibition by the
PI3K inhibitor Ly294002 (Figure 7B). We also observed
inhibition of SLY1-phosphorylation by treatment with
Rapamycin, which has not been previously reported in
peripheral lymphocytes and might reflect a differential
regulation in thymocytes (Figure 7B). Interestingly, we
detected a high degree of basal phosphorylation of SLY1
in early developing DN3 and DN4 thymocytes isolated ex
vivo, suggesting a requirement of the phosphorylated var-
iant of SLY1 in T cell development (Figure 7C). In DN3
thymocytes, the ratio of preTCR-expressing thymocytes is
low and also gated preTCR-negative DN thymocytes
exhibited increased apoptosis induction (Figure 6C, left
panel), arguing against a role downstream of the preTCR.
Therefore, we reasoned that SLY1 might be independently
phosphorylated of preTCR-mediated signalling in early
thymocytes. To test this hypothesis, RAG1-/- DN thymo-
cytes unable to rearrange the TCR-genes and therefore
lacking preTCR-signalling were incubated over night on
OP9 cells, sorted and then SLY1-phosphorylation was
detected via Western blotting (Figure 7D, left panel).
Indeed, we observed preTCR-independent phosphoryla-
tion of SLY1 in DN thymocytes as anticipated and in line
with previous data. In addition, we detected an increase in
SLY1 phosphorylation in RAG1-/- thymocytes stimulated
with Notch ligand. Unexpectedly, this Notch-induced
increase in phosphorylation was only observed inBMC Immunology 2009, 10:38 http://www.biomedcentral.com/1471-2172/10/38
Page 10 of 14
(page number not for citation purposes)
preTCR-deficient thymocytes. In preTCR-sufficient
RAG1+/+  DN thymocytes, SLY1 phosphorylation was
diminished upon Notch signalling (Figure 7D, right
panel). This data suggests a role for SLY1 in integrating
signals derived from the preTCR and from the Notch
receptor leading to prevention of premature apoptosis ini-
tiation in developing thymocytes.
Discussion
T cell development is a tightly regulated process involving
numerous successive steps of differentiation. Of particular
importance for the maturation of αβ T cells is the success-
ful rearrangement of the VDJ genes coding for the TCRβ
chain which then pairs with the preTα chain to initiate
preTCR signalling [1,27-29]. In the present work, induc-
tion of programmed cell death in DN3 thymocytes could
be precisely recapitulated as being principally dependent
on intracellular preTCR expression, thereby supporting
preTCR-signalling as the major decisive constraint in
death versus survival decision. Furthermore, the orphan
adapter protein SLY1 was identified as a novel anti-apop-
totic protein required for developmental progression of T
cell precursors to the DP stage. This anti-apoptotic func-
tion resulted in protection of thymocytes from premature
programmed cell death initiation at the DN3 thymocyte
stage. As a consequence, thymocyte DP number and there-
fore total thymus cellularity was severely reduced in SLY1-
targeted mice.
Regulation of SLY1 phosphorylation in thymocytes Figure 7
Regulation of SLY1 phosphorylation in thymocytes. A. Phosphorylation of SLY1 at serine27 in peripheral splenocytes. 
CD90+ MACS-isolated T cells were stimulated with αCD3 (10 μg/ml) for the indicated time and analysed by Western blotting. 
B. Thymocytes were left unstimulated or incubated for 20' with 20 ng/ml PDBU. Where indicated, cells had been pretreated 
with Rapamycin (20 nM) or Ly294002 (10 μM) for 1 hour. C. DN3 and DN4 thymocytes were single-cell-sorted according to 
the expression of CD90, CD25 and CD44, lysed and analysed by Western blotting. D. RAG1-/- or RAG1+/+ DN3 thymocytes 
were plated over night on OP9 cells. DN thymocytes were then sorted by single-cell flow cytometry, lysed and analysed by 
Western blotting.
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Haematopoietic progenitors entering the thymus via the
bloodstream depend on a sustained Notch receptor-lig-
and engagement to develop towards the T cell lineage
[2,6,30,31]. The OP9 differentiation system can be used
to recapitulate the signals required for haematopoietic
precursor cells to undergo T cell development until the DP
thymocyte stage in vitro. This differentiation system was
used to further elucidate the underlying defect responsible
for the reduced cellularity of SLY1-/- and SLY1Δ/Δ thymi. As
anticipated from the ex vivo situation, a reduction in pro-
liferation and differentiation upon OP9 culture relative to
littermate controls was found. Thus, a migration defect of
progenitor cells with a subsequent reduction in thymic
repopulation capacity as the major cause for the resulting
defect in thymic cellularity could be excluded. Further-
more, it could be clearly shown that the reduction in thy-
mocyte proliferation is cell intrinsic and that the principal
defect is not influenced by differences in thymic environ-
ment derived from stromal cells.
Yet Notch signalling is not only mandatory for commit-
ment to the T cell lineage. Recently, it was also shown to
be crucial for inducing a replication-competent status in
thymocytes once preTCR signalling is initiated [10,12,13].
A prerequisite for cellular expansion is an increased meta-
bolic activity including elevated expression of nutrient
receptors and protein synthesis. The activity of mTOR has
a key role in controlling this process. In peripheral T cells,
growth factors have been reported to modulate Akt and
mTOR activity and thereby to increase survival of T cells
[32]. Growth factor withdrawal resulted in metabolic col-
lapse and loss of nutrient receptor expression. In SLY1-/-
and SLY1Δ/Δ thymocytes, induced expression of the nutri-
ent receptors CD71 and CD98 as well as S6 Kinase activa-
tion were impaired relative to wt littermates. This
diminished mTOR activity correlated with a reduced cell
size increase. Therefore a defect in metabolic activity in
SLY1-defective thymocytes can be inferred, leading to
increased cell death rate and concomitant reduction of
thymic cellularity.
Full mTOR activation in DN thymocytes is dependent on
both Notch- and preTCR-derived signals [10,12,13].
There is limited insight into the signal integration process
of both pathways in thymocytes. Current literature data
suggests that signal integration occurs at the level of
PI3Kinase activation. Notch signalling is thought to
decrease expression of PTEN, the negative regulator of
PI3Kinase activation [33]. preTCR-formation is thought
to activate Akt, probably also via PI3Kinase activation
[34]. It is not precisely clear how the presence of a preTCR
without ligand engagement leads to the activation of Akt,
and whether there are also more direct interactions of the
Notch pathway with the PI3Kinase pathway which are not
regulated by transcription. The present work may add
insight into how the different signals are processed by
connecting them with the orphan adapter protein SLY1.
The reduced frequency of SLY1-/- and SLY1Δ/Δ progenitor
cells with increased metabolic activity suggests a role for
SLY1 in transmitting signals from either the preTCR or the
Notch receptor to mTOR, or even for integrating signals
from both receptors. As opposed to reports from periph-
eral T lymphocytes showing that SLY1 phosphorylation is
strictly dependent on TCR-stimulation, we have shown in
this study that SLY1-phosphorylation in thymocytes is
independent of the preTCR. Interestingly, we have found
that the phosphorylation of SLY1 at serine27 is differen-
tially regulated upon Notch-stimulation dependent on
the absence or presence of preTCR-signalling. This differ-
ing phosphorylation could be interpreted as a signal inte-
gration process of the two converging pathways
downstream of the Notch receptor and downstream of the
preTCR.
When cultured on OP9 DL-1 and OP9 GFP control cells,
the anti-apoptotic function of SLY1 was independent of
preTCR- and Notch-derived signals, indicating a general
pro-survival role for SLY1 protein independent of both
receptors. However, OP9 GFP cells have been reported to
express mRNA for the Notch ligands jagged-1 and jagged-
2, although in low amounts [6]. Therefore, it cannot be
excluded that there might still be residual Notch-signals
available to thymocytes cultivated on OP9 GFP control
cells. In addition, OP9 cells secrete or present other
unknown factors required by haematopoietic precursor
cells. These residual signals induced by unknown factors
could therefore transmit anti-apoptotic signals which are
not properly transmitted in SLY1-defective thymocytes
cultivated on OP9 GFP cells compared to the situation in
SLY1+/+ thymocytes. In addition, freshly isolated thymo-
cytes have already been receiving Notch signals during
their sojourn in the thymus in vivo, and therefore the
increased apoptosis induction of SLY1-defective thymo-
cytes on OP9 GFP cells compared to SLY1+/+ thymocytes
could already have been initiated in the thymus in vivo
before isolation of the cells. Yet unexpected is the observa-
tion that Notch signalling can even drive thymocytes into
apoptosis if they fail to generate a preTCR as observed
upon OP9 culture of DN3 thymocytes in the present
work. In contrast to this notice, Notch signalling in DN3
thymocytes is thought to play a general anti-apoptotic
role by activating the Akt kinase pathway [12]. This study
therefore adds additional complexity to the effector func-
tions of Notch signalling in DN3 thymocytes, implying a
pro-apoptotic outcome of Notch receptor activation in a
certain cellular context.
As previously described, SLY1Δ/Δ mice expressing a SLY1
protein harbouring a partial deletion in the N-terminal
region show impaired immune responses [16,17]. The
region missing in SLYΔ contains part of a bipartite nuclear
localisation sequence and the known phosphorylationBMC Immunology 2009, 10:38 http://www.biomedcentral.com/1471-2172/10/38
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site closely associated to the potential localisation
sequences. As a consequence, the subcellular localisation
of SLY1Δ is shifted from a nucleocytoplasmic to a strictly
cytoplasmic localisation [16]. The putative protein-pro-
tein interacting SH3- and SAM-domains remain intact in
SLY1Δ, possibly still enabling its interference with other
signalling proteins. However, a dominant negative effect
of SLY1Δ can be excluded due to the comparable pheno-
type of SLY1-/- mice. One conclusion that can be drawn
from this data is that an essential function, at least for T
cell development, of SLY1 is mediated by the amino acids
at position 20–100. An apparent role for this deleted
region could be either to regulate the correct subcellular
localisation of the protein or to be directly required for
interaction with SLY1 binding partners by providing a
sequence specific recognition signal.
Conclusion
In the present work, SLY1 is described as a novel anti-
apoptotic protein required for thymocyte development by
preventing DN thymocytes from premature initiation of
programmed cell death. SLY1-negative thymocytes exhib-
ited impaired activation of the mTOR complex, support-
ing an essential role of mTOR in thymocyte development.
We therefore propose a role for SLY1 in signal integration
of the Notch receptor and preTCR pathways culminating
in the activation of the mTOR protein complex in devel-
oping thymocytes. As the sly1 gene is located on the X-
chromosome in man, its function could be either nega-
tively affected in some cases of x-linked immunodefi-
ciency or activating mutations could contribute to
lymphoma development. In the future, the identification
of the interacting kinase and the precise molecular mech-
anism by which SLY1 contributes to mTOR activation and
prevention of programmed cell death will be of great
interest.
Methods
RNA isolation and RT-PCR
Total RNA from cells was isolated using Trizol Reagent
(Invitrogen) according to the manufacture's instructions.
First-strand cDNA synthesis was performed using 1 μg of
total RNA with M-MLV reverse transcriptase and oligo dT
primer (Invitrogen).
SLY1 transcripts were amplified with
SLY1_exon6_forward: 5'-CCC GGA GGA TTC TGG GAA
GA-3' and SLY1_exon8_reverse: 5'-GAA GTC AGT GTG
GAC TCG GG-3'. The following primer sequences were
used to amplify GAPDH: (forward) 5'-CAT GTA GGC CAT
GAG GTC CAC CAC-3' and (reverse) 5'-TGA AGG TCG
GTG TGA ACG GAT TTG GC-3'.
Gene targeting and mice
Generation of SLYΔ/Δ  mice and genotyping has been
described previously [16]. For generation of SLY-/- mice,
E14.1 embryonic stem (ES) cells from 129/Ola mice were
grown in Dulbecco's modified Eagle's medium (Invitro-
gen, Carlsbad, CA, USA) supplemented with 2 mM
glutamine (Seromed, Wien, Austria), leukemia inhibitory
factor, 100 U/ml penicillin, 100 μg/ml streptomycin (Ser-
omed), 50 μM 2-mercaptoethanol (Invitrogen) and 15%
heat-inactivated fetal bovine serum (Pan Biotech, Aiden-
bach, Germany). Genomic fragments flanking the murine
sly1 gene as well as neomycin and thymidine kinase were
cloned into pBluescript (Agilent technologies, Santa
Clara, CA, USA) and fully sequenced. The targeting vector
was designed in such a way that the neomycin resistance
cassette was inserted in reverse orientation in exon 1 of the
sly1  gene 3' of the starting ATG without deleting any
endogenous sequence. E14.1 ES cells were electroporated
with the NotI-linearized targeting vector, and the trans-
fected cells were subsequently subjected to G418 and gan-
ciclovir selection. Clones carrying the correct homologous
recombination were identified by Southern blot hybridi-
zation with the 5' flanking probe indicated in Figure 1
after digestion of ES cell DNA with EcoRV and BamHI.
Single integration was verified by probing the Southern
blot with the neomycin resistance cassette. Correctly tar-
geted ES cell clones were injected into C57BL/6 blasto-
cysts, which were transferred into pseudopregnant foster
mice. Resulting chimeric mice were backcrossed to
C57BL/6 mice, and germ line transmission of the targeted
allele was again confirmed by Southern blot analysis.
SLY1-/- mice were backcrossed to the C57BL/6 background
for six to ten generations. Wild-type littermates were used
as controls. Genotyping of SLY1 knockout mice was per-
formed by PCR with the following primers: 5'-TGA CGG
CAG TAG GGA TGG TAG-3' (forward); 5'-CGC CTT CTT
GAC GAG TTC TTC T-3' (neo reverse); 5'-AGT GGC CTG
GGG GAG ATG T-3' (Wt reverse). SLY1Δ/Δ mice were back-
crossed for twelve generations.
Mice were kept according to national guidelines for ani-
mal care in an SPF animal facility. All animal work was
performed according to the guidelines of the German
national animal care regulations. RAG1-/- mice were pur-
chased from Jackson Laboratories.
Flow cytometric analysis
Antibodies conjugated to fluorescein isothiocyanate, phy-
coerythrin, allophycocyanin, percp, phycoerythrin-cy7,
allophycocyanin-cy7 and biotin were obtained from
either Pharmingen (San Diego, CA, USA), Southern Bio-
tech (Birmingham, Alabama, USA) or eBioscience (San
Diego, CA, USA). Alexa-fluor488-conjugated anti-phos-
pho-Akt and anti-phospho-S6 antibodies were obtained
from Cell Signalling (Danvers, MA, USA). Cells were
stained with saturating concentrations of antibody in
accordance with the manufacturer's instructions. Data
were acquired with either a FACSCalibur or FACSCanto
(Becton Dickinson, Franklin Lakes, NJ, USA) using Cel-BMC Immunology 2009, 10:38 http://www.biomedcentral.com/1471-2172/10/38
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lquest or DIVA (Becton Dickinson) software and were
analysed using Flowjo software (Treestar, San Carlos, CA,
USA). Viable cells were gated according to their forward
and sideward scatter profiles and DAPI (Invitrogen) exclu-
sion. CD4 and CD8 DN Thy1.2+ subsets were gated by lin-
eage exclusion of CD4 and CD8 DP and SP cells and
TCRγδ. DN subsets were further subdivided by CD25 and
CD44 expression, defining CD25-CD44+  as DN1,
CD25+CD44+ as DN2, CD25+CD44- as DN3 and CD25-
CD44- as DN4, respectively. Cellular DNA content was
measured by DAPI staining of methanol permeabilised
cells. Phospho-S6 and phospho-Akt levels were assessed
as described previously [11].
OP9 cultures and assay
OP9 bone marrow stromal cells expressing Notch ligand
Delta Like-1 (DL-1) and control OP9 cells [6] were a gift
from Juan Carlos Zúñiga-Pflücker (Toronto, Canada).
OP9 cells were maintained in α MEM (Invitrogen) supple-
mented with 50 μM 2-mercaptoethanol, 100 U/ml peni-
cillin, 1 mg/ml streptomycin and 20% heat-inactivated
FBS. Sorted DN thymocytes were co-cultured on OP9 DL-
1 or OP9 control cells for the indicated time periods. DN
thymocytes were obtained using an AutoMACS (Miltenyi
Biotech, Bergisch-Gladbach, Germany) magnetic cell
sorter by depleting CD4+ and CD8+ thymic subpopula-
tions to greater than 97% purity. DN3 or DN4 cells were
obtained by subsequently either positively sorting or
depleting CD25-expressing DN3 cells, respectively. Alter-
natively, DN3 cells were obtained by sorting with a FAC-
SAria single cell sorter (Becton Dickinson, Heidelberg,
Germany) with greater than 98% purity. On the day of
harvest thymocytes were filtered through 50 μm filters to
remove OP9 cells before assessing developmental pro-
gression and proliferation of T lineage cells.
Western blot analysis
Thymocytes or splenocytes were resuspended in lysis
buffer containing 10 mMNaF, 1 mM sodium orthovanad-
ate and protease inhibitor cocktail (Sigma) on ice for15
min. Lysates were separated by SDS-PAGE and transferred
to nitrocellulose membranes (Perkin-Elmer, Rodgau-
Jügesheim). After blocking with 5% milk in TBST, mem-
branes were probed with primary antibodies and subse-
quently detected using horseradish peroxidase-linked
goat anti-mouse or anti-rabbit IgG and visualized by the
enhanced chemilumescent (ECL) detection system (GE
Healthcare, Munich, Germany). Membranes were rep-
robed with anti-β-actin (Sigma, St. Louis, Missouri, USA).
The anti-SLY1 antibody has been generated by Eurogentec
(Seraing, Belgium) and has already been described [16].
Anti-phospho-SLY1 antibodies also have been generated
by Eurogentec by immunizing rabbits with oligopeptide
(H2N-LQR SSpS FKD FAK C-CONH2). Both antibodies
have been tested extensively for specificity (data not
shown).
Statistical analyses
Statistical significance of differences between wildtype
and SLY1-targeted mice were evaluated using the Students
t test. P < 0.05 was considered significant. All results are
presented as mean values ± SEM.
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Additional material
Additional file 1
SLY1 is expressed in all major thymocyte subsets. Semi-quantitative RT-
PCR. Thymocytes were sorted according to their surface expression of CD4 
and CD8. Subsequently, RNA was isolated and transcribed into cDNA. 
A serial 1:3 dilution of cDNA was used to amplify SLY1 or GAPDH tran-
scripts with SLY1- or GAPDH-specific primers, respectively. Zipped folder 
containing EPS file.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-38-S1.zip]
Additional file 2
Proliferation and differentiation defect of sorted SLY1-/- and SLY1Δ/Δ 
DN3 thymocytes cannot be rescued by adding IL-7. A. Fold expansion 
of sorted DN3 thymocytes after six days of culture on OP9 DL-1 cells. If 
indicated, 1 ng/ml mIL-7 was included in the cultures. B. Differentiation 
rate of sorted DN3 thymocytes after six days of culture on OP9 DL-1 cells 
without IL7. C. Differentiation rate of sorted DN3 thymocytes after six 
days of culture on OP9 DL-1 cells with 1 ng/ml murine IL7. Data are 
based on triplicate analyses. The differentiation rate corresponds to the 
percentage of DP cells divided by the percentage of remaining DN cells. 
The expansion rate was determined by comparing the obtained cell 
number on day six to initial seeding numbers on day 0. Representative 
data of two independently performed experiments is shown. Zipped folder 
containing EPS file.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-38-S2.zip]
Additional file 3
Notch- and preTCR-dependent activation of mTOR results in cell size 
increase and is diminished in sorted DN SLY1-/- and SLY1Δ/Δ thymo-
cytes. A. mTOR activation is strictly dependent on a combined preTCR- 
and Notch receptor-derived signal. Cell size of DN thymocytes was ana-
lysed after 12 h culture on OP9 GFP or OP DL-1 cells. Cells were gated 
on intracellular TCRβ-positive or -negative. B. Cell size overlay of DN 
SLY1+/+, SLY1-/- and SLY1Δ/Δ preTCR-positive thymocytes cultured on 
OP9 DL-1 cells. As a control, 20 nM Rapamycin was added during the 
cultivation period to inhibit mTOR activation. Zipped folder containing 
EPS file.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-38-S3.zip]BMC Immunology 2009, 10:38 http://www.biomedcentral.com/1471-2172/10/38
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Additional file 4
γ-Secretase-inhibitor (GSI) titration of OP9-cultured DN3 cells. 
Sorted SLY1+/+, SLY1-/- and SLY1Δ/Δ DN3 thymocytes were cultured on 
OP9 DL-1 or OP9 GFP cells for six days before analysis. Then, CD4- and 
CD8-expression was assessed by FACS (left panel). The expansion rate 
based on initial seeding numbers was determined (right panel). *p <0.01; 
**p <0.001; *** p <0.0001. Zipped folder containing EPS file.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-10-38-S4.zip]